Atenativ Effect on Uterine Blood Flow and Preeclampsia
Study Details
Study Description
Brief Summary
The study will be an open controlled pilot study of 6 patients with early-onset severe preeclampsia. Patients will receive Atenativ in addition to conventional therapy The patients will be followed up within the study until three days after delivery. Laboratory analyses and uterine and umbiliacal blood flow will be determined.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Detailed Description
The study will be an open controlled pilot study of 6 patients with early-onset severe preeclampsia. Patients will receive Atenativ in addition to conventional therapy The patients will be followed up within the study until three days after delivery. In addition to conventional therapy, i.v. administration of Atenativ will be given in a dosage aimed to raise the plasma level of AT initially to 120% (1.2 kIU/L) The goal is to achieve and maintain plasma activity of about 100% during two weeks. The dose of Atenativ is based on the actual plasma level of AT measured 2 hours before the dose. During the first two days of treatment plasma samples will be drawn for the measurement of AT activity twice a day, once before and 12 hours after infusion in order to monitor the dosage. Thereafter and until study discontinuation AT will be measured once a day. The treatment will continue for two weeks if plasma AT III is below 100% (1.0 kIU/L).Uterine blood flow is measured before, during and after the AT infusion. Demographic data, medical history and other background data (age, weight, height, gestational week, smoker or not, gravidity, parity, previous hypertension, previous medication etc) will be recorded in order to ensure that the inclusion criteria are met and to verify patient identity and inclusion status. The week of gestation when the patient is included in the study as well as the week of gestation at delivery is recorded.
The type of delivery (vaginal or caesarean section as well as planned or acute) will also be recorded.. General haemostatic parameters are to be analyzed before start of treatment and then every day during treatment and thereafter at least twice a week. Special haemostatic parameters are Placental growth factor, S-Flt-1, VEGF and Syndecan-1. They will be sampled before start of treatment and during treatment once a week. The samples will be collected and frozen and not analyzed before the termination of the study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Consisting of treatment with Atenativ During two weeks antithrombin concentrate(Atenativ) will be administered in order to maintain normal levels of antithrombin |
Drug: Atenativ
intravenous transfusion
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Blood flow in uterin and umbilical artery [up to day 14]
Secondary Outcome Measures
- fetal outcome [at birth]
CTG, blood flow, Apgar score, birthweight
- bleeding complications [during pregnancy and at delivery]
measurements of bleeding before and after placenta delivery
Other Outcome Measures
- Biomarkers of endothelial damage [up to day 14]
S-Flt-1, VEGF,Syndecan-1
- Atenativ concentrate [treatment during 2 weeks]
amount needed to maintain normal antithrombin levels
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Pregnant woman in gestational week 23+0 - 29+0
-
Severe preeclampsia as defined by international criteria (1,2)
-
Blood pressure >160/110 mmHg (measured twice 30 minutes apart). proteinuria (>5 .0 g/L per 24 hours or >3 + labstick in at least two random samples six hours apart) after 20th gestational week.
-
Blood pressure >140/90 mmHg and proteinuria >5.0 g/24 h.
-
preeclampsia ( blood pressure > 140/90 and proteinuria >0.3 g/24 h) with IUGR or subjective symptoms as epigastic pain (HELLP), headache, dizziness or visual disturbancies, oligouri < 600 ml/24 h, coagulation disturbancies.
- AT level <0.8 kIE/L
Exclusion Criteria:1. History of congenital AT deficiency 2. Severe preeclampsia with demand on acute delivery within 24 hours according to the investigators judgments 3. Concomitant administration of anticoagulants and platelet inhibitors within 2 weeks 4. Chronic renal disease 5. Diabetes melittus or gestational diabetes 6. Intrauterine fetal death 7. Participation in another clinical study 8. Multiple pregnancies
-
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Dept Obstetrics, Sahlgrenska University Hospital | Gothenburg | Sweden | 41685 |
Sponsors and Collaborators
- Vastra Gotaland Region
- Octapharma
Investigators
- Principal Investigator: Margareta Hellgren, MD,PhD,prof, department Obstetrics, Sahlgrenska University Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- EudraCT 2012-005770-57